Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/179984
Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZMONO) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZCOMBO) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZMONO and 31 (57.4%) on TCZCOMBO: MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZCOMBO were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.
Citació
Citació
PRIETO PEÑA, Diana, BERNABEU, Pilar, VELA, Paloma, NARVÁEZ, Javier, FERNÁNDEZ LÓPEZ, Jesús c., FREIRE GONZÁLEZ, Mercedes, GONZÁLEZ ÁLVAREZ, Beatriz, SOLANS LAQUÉ, Roser, CALLEJAS RUBIO, José luis, ORTEGO CENTENO, Norberto, FERNÁNDEZ DÍAZ, Carlos, RUBIO, Esteban, GARCÍA MORILLO, Salvador, MINGUEZ, Mauricio, FERNÁNDEZ CARBALLIDO, Cristina, MIGUEL, Eugenio de, MELCHOR, Sheila, SALGADO PÉREZ, Eva, BRAVO, Beatriz, ROMERO YUSTE, Susana, SALVATIERRA, Juan, HIDALGO, Cristina, MANRIQUE ARIJA, Sara, ROMERO GÓMEZ, Carlos, MOYA, Patricia, ÁLVAREZ RIVAS, Noelia, MENDIZABAL, Javier, ORTIZ SANJUÁN, Francisco, PÉREZ DE PEDRO, Iván, ALONSO VALDIVIELSO, José l., PÉREZ SÁNCHEZ, Laura, ROLDÁN, Rosa, FERNANDEZ-LLANIO, Nagore, GÓMEZ DE LA TORRE, Ricardo, SUAREZ, Silvia, MONTESA CABRERA, María jesús, DELGADO SÁNCHEZ, Mónica, LORICERA, Javier, ATIENZA MATEO, Belén, CASTAÑEDA, Santos, GONZÁLEZ GAY, Miguel a., BLANCO, Ricardo. Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review. _Therapeutic Advances in Musculoskeletal Disease_. 2021. Vol. 13, núm. 1759720-2110209. [consulta: 3 de febrer de 2026]. ISSN: 1759-7218. [Disponible a: https://hdl.handle.net/2445/179984]